Literature DB >> 22954699

Prognostic value of aberrant hypermethylation in pleural effusion of lung adenocarcinoma.

Maribel Botana-Rial1, Loretta De Chiara, Diana Valverde, Virginia Leiro-Fernández, Cristina Represas-Represas, Victor Del Campo-Pérez, Alberto Fernández-Villar.   

Abstract

Lung adenocarcinoma is one of the most frequent causes of malignant pleural effusions (MPE). The presence of MPE bears a poor prognosis. Although epigenetic changes are commonly related to human neoplasia, scarce date is available on patients with MPE. We aimed to estimate the prognostic value of DNA methylation of tumor suppressor genes from pleural fluid. Thirty patients with MPE due to lung adenocarcinoma were prospectively included. Methylation-specific (MS) PCR was used to study the methylation status of the promoter region of tumor suppressor genes p16/INK4a, MGMT, BRCA1 and RARβ in pleural fluid. Clinical data and survival were collected. Survival analysis was performed using Kaplan-Meier plots and Cox regression. Hypermethylation in at least one gene was detected in 25 patients (83.3%). On multivariate analysis factors significantly associated with shorter survival were the lack of hypermethylation in any of the studied genes (hazard ratio = 9.3; p = 0.001), Charlson index ≥ 3 (hazard ratio = 9.6, p = 0.002) and no oncological treatment (hazard ratio = 11.1; p < 0.001). Analysis of aberrant promoter hypermethylation of tumor suppressor genes may be useful in predicting prognosis, but further studies are needed to validate our findings.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22954699      PMCID: PMC3542234          DOI: 10.4161/cbt.22004

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  26 in total

Review 1.  Management of malignant pleural effusions.

Authors:  V B Antony; R Loddenkemper; P Astoul; C Boutin; P Goldstraw; J Hott; F Rodriguez Panadero; S A Sahn
Journal:  Eur Respir J       Date:  2001-08       Impact factor: 16.671

2.  Can we improve the cytologic examination of malignant pleural effusions using molecular analysis?

Authors:  Malcolm V Brock; Craig M Hooker; Rex Yung; Mingzhou Guo; Yu Han; Stephen E Ames; David Chang; Stephen C Yang; David Mason; Marc Sussman; Stephen B Baylin; James G Herman
Journal:  Ann Thorac Surg       Date:  2005-10       Impact factor: 4.330

3.  Prognostic implication of aberrant promoter hypermethylation of CpG islands in adenocarcinoma of the lung.

Authors:  Young Tae Kim; Sun Jung Park; Seung Hee Lee; Hee Jung Kang; Seokyung Hahn; Chang Hyun Kang; Sook Whan Sung; Joo Hyun Kim
Journal:  J Thorac Cardiovasc Surg       Date:  2005-10-13       Impact factor: 5.209

4.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

5.  Can aberrant promoter hypermethylation of CpG islands predict the clinical outcome of non-small cell lung cancer after curative resection?

Authors:  Young Tae Kim; Seung Hee Lee; Sook Whan Sung; Joo Hyun Kim
Journal:  Ann Thorac Surg       Date:  2005-04       Impact factor: 4.330

6.  Methylation profiling of archived non-small cell lung cancer: a promising prognostic system.

Authors:  A Mazin Safar; Horace Spencer; Xiaobo Su; Maureen Coffey; Craig A Cooney; Luke D Ratnasinghe; Laura F Hutchins; Chun-Yang Fan
Journal:  Clin Cancer Res       Date:  2005-06-15       Impact factor: 12.531

7.  Potential diagnostic value of methylation profile in pleural fluid and serum from cancer patients with pleural effusion.

Authors:  Susana Benlloch; Jose Marcelo Galbis-Caravajal; Concepcion Martín; Jose Sanchez-Paya; Jose Manuel Rodríguez-Paniagua; Santiago Romero; Juan Jose Mafe; Bartomeu Massutí
Journal:  Cancer       Date:  2006-10-15       Impact factor: 6.860

Review 8.  Epigenetic modifications in cancer.

Authors:  R Kanwal; S Gupta
Journal:  Clin Genet       Date:  2011-12-08       Impact factor: 4.438

9.  Multilevel and continuous pleural fluid pH likelihood ratios for evaluating malignant pleural effusions.

Authors:  John E Heffner; John N Heffner; Lee K Brown
Journal:  Chest       Date:  2003-06       Impact factor: 9.410

10.  Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene.

Authors:  Cuiju Wang; Akiko Horiuchi; Tsutomu Imai; Satoshi Ohira; Kazuko Itoh; Toshio Nikaido; Yoshihiko Katsuyama; Ikuo Konishi
Journal:  J Pathol       Date:  2004-02       Impact factor: 7.996

View more
  4 in total

1.  Diagnostic value of tumor markers for lung adenocarcinoma-associated malignant pleural effusion: a validation study and meta-analysis.

Authors:  Mei Feng; Jing Zhu; Liqun Liang; Ni Zeng; Yanqiu Wu; Chun Wan; Yongchun Shen; Fuqiang Wen
Journal:  Int J Clin Oncol       Date:  2016-12-18       Impact factor: 3.402

2.  Prognostic value of p16, p53, and pcna in sarcoma and an evaluation of immune infiltration.

Authors:  Dechao Cai; Xiao Ma; Huihui Guo; Haotian Zhang; Ashuai Bian; Haoran Yu; Wendan Cheng
Journal:  J Orthop Surg Res       Date:  2022-06-10       Impact factor: 2.677

Review 3.  Prognosis value of MGMT promoter methylation for patients with lung cancer: a meta-analysis.

Authors:  Chao Chen; Haiqing Hua; Chenglong Han; Yuan Cheng; Yin Cheng; Zhen Wang; Jutao Bao
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

Review 4.  Liquid biopsies based on DNA methylation as biomarkers for the detection and prognosis of lung cancer.

Authors:  Peilong Li; Shibiao Liu; Lutao Du; Ghazal Mohseni; Yi Zhang; Chuanxin Wang
Journal:  Clin Epigenetics       Date:  2022-09-24       Impact factor: 7.259

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.